In this investigation in AML patients, we have utilized plasma metabolomics to examine the metabolic consequences of IDH1 and IDH2 genotype determined from either peripheral blood mononuclear cells (PBMCs) or bone marrow mononuclear cells (BMMCs). This evidence concerns the gene IDH2 and acute myeloid leukemia.